Abstract | OBJECTIVE: To review clinical features of dementia with Lewy bodies (DLB) and to guide family physicians in pharmacologic management, including medications to avoid. QUALITY OF EVIDENCE A MEDLINE: search of literature from 1995 to 2002 used the MeSH terms dementia with Lewy bodies/diagnosis, dementia with Lewy bodies/ therapy, and antipsychotics/ dementia with Lewy bodies. Level II and III evidence was available for diagnosis and treatment of DLB. One randomized controlled trial of rivastigmine was reviewed and appraised. MAIN MESSAGE: CONCLUSION: Recognition and diagnosis of DLB is important to optimize pharmacologic management and to minimize risk of adverse reactions to neuroleptics.
|
Authors | Christopher Frank |
Journal | Canadian family physician Medecin de famille canadien
(Can Fam Physician)
Vol. 49
Pg. 1304-11
(Oct 2003)
ISSN: 0008-350X [Print] Canada |
PMID | 14594099
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antiparkinson Agents
- Antipsychotic Agents
- Cholinesterase Inhibitors
|
Topics |
- Antiparkinson Agents
(therapeutic use)
- Antipsychotic Agents
(therapeutic use)
- Cholinesterase Inhibitors
(therapeutic use)
- Humans
- Lewy Body Disease
(diagnosis, drug therapy)
|